Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

[1]  Matthew S. Miller,et al.  Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2 , 2022, Cell.

[2]  Fan Wang,et al.  Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques , 2022, Emerging microbes & infections.

[3]  Wei Chen,et al.  Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial , 2022, Nature Medicine.

[4]  N. Andrews,et al.  Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines , 2022, The New England journal of medicine.

[5]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[6]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.

[7]  V. Libri,et al.  Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial , 2021, The Lancet.

[8]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[9]  M. Peiris,et al.  A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac , 2021, medRxiv.

[10]  Shinn-Jang Hwang,et al.  Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan , 2021, The Lancet Respiratory Medicine.

[11]  A. U. Keskin,et al.  SARS‐CoV‐2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two‐dose CoronaVac vaccine regimen , 2021, Journal of medical virology.

[12]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[13]  X. Guo,et al.  Heterologous prime-boost immunization with CoronaVac and Convidecia , 2021, medRxiv.

[14]  V. Libri,et al.  Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.

[15]  E. Lavelle,et al.  Mucosal vaccines — fortifying the frontiers , 2021, Nature Reviews Immunology.

[16]  Yu-An Kung,et al.  Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards , 2021, medRxiv.

[17]  J. Klingström,et al.  Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.

[18]  Xiaohong Song,et al.  Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial , 2021, The Lancet Infectious Diseases.

[19]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[20]  Stephanie S. Chen,et al.  Emergence of a Novel SARS-CoV-2 Variant in Southern California. , 2021, JAMA.

[21]  E. A. Moreira,et al.  T resident helper cells promote humoral responses in the lung , 2021, Science Immunology.

[22]  B. Graham,et al.  T cell immunity to SARS-CoV-2 following natural infection and vaccination , 2020, Biochemical and Biophysical Research Communications.

[23]  Y. Hu,et al.  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.

[24]  G. Gao,et al.  Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.

[25]  Y. Hu,et al.  Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.

[26]  Jaap Goudsmit,et al.  Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.